Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Largest Data Set of Cancer-Related Genetic Variations Generated for Researchers

By BiotechDaily International staff writers
Posted on 29 Jul 2013
US scientists have generated a data set of cancer-specific genetic variations and are making these data available to the research community.

The investigators, from the US National Cancer Institute (NCI; Bethesda, MD, USA), published their study’s findings July 15, 2013, online in Cancer Research, a journal of the American Association for Cancer Research.

This new technology will help cancer researchers better illuminate drug response and resistance to cancer treatments. “To date, this is the largest database worldwide, containing six billion data points that connect drugs with genomic variants for the whole human genome across cell lines from nine tissues of origin, including breast, ovary, prostate, colon, lung, kidney, brain, blood, and skin,” said Yves Pommier, MD, PhD, chief of the laboratory of molecular pharmacology at the NCI in an interview. “We are making this data set public for the greater community to use and analyze. Opening this extensive data set to researchers will expand our knowledge and understanding of tumorigenesis, as more and more cancer-related gene aberrations are discovered. This comes at a great time, because genomic medicine is becoming a reality, and I am very hopeful this valuable information will change the way we use drugs for precision medicine.”

Dr. Pommier and colleagues conducted whole-exome sequencing of the NCI-60 human cancer cell-line panel, which is an assortment of 60 human cancer cell lines, and generated a comprehensive list of cancer-specific genetic variations. Early research conducted by the researchers show that the extensive data set has the potential to greatly enhance understanding of the links between specific cancer-related genetic variations and drug response, which will hasten the drug development process.

The NCI-60 human cancer cell-line panel is used extensively by cancer researchers to discover novel anticancer drugs. To conduct whole-exome sequencing, Dr. Pommier and his NCI team extracted DNA from the 60 different cell lines from tumors of the lung, colon, brain, ovary, prostate, breast, and kidney, as well as melanoma and leukemia, and cataloged the genetic coding variants for the complete human genome. The genetic variations identified were of two types: type I variants corresponding to variants found in the normal population, and type II variants, which are cancer-specific.

The scientists then employed the Super Learner algorithm to predict the sensitivity of cells harboring type II variants to 103 anticancer drugs approved by the US Food and Drug Administration (FDA) and an additional 207 investigational new pharmaceutical agents. They were able to assess the correlations between key cancer-related genes and clinically pertinent anticancer drugs, and predict the outcome.

The data generated in this project provide a way to identify new determinants of response and processes of drug resistance, and offer opportunities to target genomic defects and overcome acquired resistance, according to Dr. Pommier. To accomplish this, the researchers are making these data available to all researchers by way of two database portals, called the CellMiner database and the Ingenuity systems database.

Related Links:
US National Cancer Institute



WATERS CORPORATION

Channels

Genomics/Proteomics

view channel
Image: Electron micrograph of Hepatitis C virus purified from cell culture. Scale bar is 50 nanometers (Photo courtesy of the Center for the Study of Hepatitis C, the Rockefeller University).

Oxidized LDL Predicts Response to Interferon Treatment of Chronic Hepatitis C and May Be a Treatment Option

Oxidized low-density lipoprotein (oxLDL) in the blood was shown to predict responsiveness to interferon treatment in patients with chronic Hepatitis C virus (HCV) infection and to inhibit spread of the... Read more

Drug Discovery

view channel
Image: Molecular model of the anti-cancer drug 5-fluorouracil (Photo courtesy of Wikimedia Commons).

Novel Microcapsule Approach Reduces Toxic Side Effects of Chemotherapy

Cancer researchers have reduced chemotherapy's toxic side effects by using nanoporous capsules to transport an enzyme to the site of a tumor where it is activated by a selective heating process to convert... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

02 Jun 2015 - 03 Jun 2015
15 Jun 2015 - 18 Jun 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.